Subject characteristics (n = 15)
Characteristic . | Value . |
---|---|
Median age, y (range) | 45 (20-68) |
Patient sex, male/female, n | 10/5 |
Donor type, n | |
Matched related donor | 7 |
Matched unrelated donor | 8 |
Graft source, n | |
Peripheral blood | 13 |
Bone marrow | 2 |
Diagnosis, n | |
Acute lymphoblastic leukemia | 3 |
Acute myeloid leukemia | 3 |
Chronic myeloid leukemia | 2 |
Chronic lymphocytic leukemia | 1 |
Mantle cell lymphoma | 1 |
Multiple myeloma | 1 |
Non-Hodgkin lymphoma | 1 |
Polycythemia vera/myelofibrosis | 1 |
Sezary syndrome | 1 |
Systemic lupus erythematosus | 1 |
Median days status after transplantation at enrollment (range) | 1270 (100-4334) |
Median no. of secondary therapies before study enrollment (range) | 3 (2-5) |
cGVHD primary therapy, n | |
Prednisone | 13 |
Prednisone/cyclosporine | 2 |
cGVHD secondary therapies, n | |
Cyclosporine | 4 |
Extracorporeal photopheresis | 8 |
Tacrolimus | 6 |
Mycophenolate mofetil | 5 |
Pentostatin | 1 |
Plaquenil | 1 |
Rituximab | 5 |
Daclizumab | 1 |
cGVHD organ involvement upon study enrollment, n | |
Skin/connective tissue | 13 |
Oropharynx | 12 |
Liver (total bilirubin) | 0 |
Liver (AST, ALT, alkaline phosphatase) | 7 |
Esophagus/lower GI | 7 |
Ocular | 9 |
Lung | 1 |
Characteristic . | Value . |
---|---|
Median age, y (range) | 45 (20-68) |
Patient sex, male/female, n | 10/5 |
Donor type, n | |
Matched related donor | 7 |
Matched unrelated donor | 8 |
Graft source, n | |
Peripheral blood | 13 |
Bone marrow | 2 |
Diagnosis, n | |
Acute lymphoblastic leukemia | 3 |
Acute myeloid leukemia | 3 |
Chronic myeloid leukemia | 2 |
Chronic lymphocytic leukemia | 1 |
Mantle cell lymphoma | 1 |
Multiple myeloma | 1 |
Non-Hodgkin lymphoma | 1 |
Polycythemia vera/myelofibrosis | 1 |
Sezary syndrome | 1 |
Systemic lupus erythematosus | 1 |
Median days status after transplantation at enrollment (range) | 1270 (100-4334) |
Median no. of secondary therapies before study enrollment (range) | 3 (2-5) |
cGVHD primary therapy, n | |
Prednisone | 13 |
Prednisone/cyclosporine | 2 |
cGVHD secondary therapies, n | |
Cyclosporine | 4 |
Extracorporeal photopheresis | 8 |
Tacrolimus | 6 |
Mycophenolate mofetil | 5 |
Pentostatin | 1 |
Plaquenil | 1 |
Rituximab | 5 |
Daclizumab | 1 |
cGVHD organ involvement upon study enrollment, n | |
Skin/connective tissue | 13 |
Oropharynx | 12 |
Liver (total bilirubin) | 0 |
Liver (AST, ALT, alkaline phosphatase) | 7 |
Esophagus/lower GI | 7 |
Ocular | 9 |
Lung | 1 |
AST indicates aspartate aminotransferase; and ALT, alanine aminotransferase.